Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis

Wanner, Christoph; Krane, Vera; März, Winfried

doi:10.1016/j.accreview.2005.09.027

Cited by 396 publications

(536 citation statements)

References 0 publications

Supporting

Mentioning

503

Contrasting

Unclassified

Order By: Relevance

“…In the absence of consensus, other factors impacting use, such as local physician or healthcare "culture" or local and regional patterns in training may have predominated. Since more recent randomized controlled trials have provided conflicting evidence on the benefits of statins, [11][12][13] it will be important to revaluate statin use in the coming years to assess what, if any, affect the recent RCTs have on prescribing patterns.…”

Section: Discussionmentioning

confidence: 99%

“…The role of these drugs in the prevention of cardiovascular events in end stage renal disease (ESRD) patients on dialysis is uncertain. Despite the completion of three randomized clinical trials (RCTs) in dialysis patients, [11][12][13] the efficacy of statins in reducing mortality or cardiovascular events has not been definitively established. This was unexpected, given both earlier observational studies that had suggested a survival benefit of statins in this population 14,15 as well as a strong underlying clinical rationale to treat these patients, given their high rates of cardiovascular disease (CVD).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients

et al. 2012

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients

et al. 2012

View full text Add to dashboard Cite

“…In one placebo, randomized controlled trial (RCT; 4D study) of 1,255 patients (460 evaluable patients who reached the primary endpoint) with ESRD secondary to diabetes, atorvastatin had no effect on CVD events [26]. The study of Heart and Renal Protection (SHARP) trial was a RCT of 9,270 patients with pre-dialysis CKD and ESRD without prior myocardial infarction or coronary revascularization.…”

Section: Impact Of Dyslipidemia On Cardiovascular Morbidity and Mortamentioning

confidence: 99%

Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease

Khurana

Silverstein

2015

Pediatr Nephrol

View full text Add to dashboard Cite

Lipids are essential components of cell membranes, contributing to cell fuel, myelin formation, subcellular organelle function, and steroid hormone synthesis. Children with chronic kidney disease (CKD) and end-stage renal disease (ESRD) exhibit various co-morbidities, including dyslipidemia. The prevalence of dyslipidemias in children with CKD and ESRD is high, being present in 39-65 % of patients. Elevated lipid levels in children without renal disease are a risk factor for cardiovascular disease (CVD), while the risk for CVD in pediatric CKD/ESRD is unclear. The pathogenesis of dyslipidemia in CKD features various factors, including increased levels of triglycerides, triglyceride-rich lipoproteins, apolipoprotein C3 (ApoC-III), decreased levels of cholesterylester transfer protein and high-density lipoproteins, and aberrations in serum very low-density and intermediatedensity lipoproteins. If initial risk assessment indicates that a child with advanced CKD has 2 or more co-morbidities for CVD, first-line treatment should consist of nonpharmacologic management such as therapeutic lifestyle changes and dietary counseling. Pharmacologic treatment of dyslipidemia may reduce the incidence of CVD in children with CKD/ESRD, but randomized trials are lacking. Lipids are essential components of cell membranes, contributing to cell fuel, myelin formation, subcellular organelle function, and steroid hormone synthesis. Lipids are generally categorized by their density and other physical characteristics [1]. Since lipids such as cholesterol and triglycerides (TG) are insoluble in plasma, lipoproteins are required to transport all sources (e.g., diet) of lipids to areas in which the lipids can either be stored for future use or used immediately [2], although it should be noted that short-and medium-chain fatty acids also flow via the portal system as fatty acids. Specifically, low-density lipoproteins (LDL) carry the majority of cholesterol (forming LDL-C), while very low-density lipoproteins (VLDL) carry the majority of triglycerides.The broad categories of lipoproteins are chylomicrons, VLDL, LDL, and high-density lipoproteins (HDL Prevalence and sub-types of dyslipidemia in pediatric chronic kidney disease (CKD) and end-stage renal disease (ESRD)Children with CKD/ESRD exhibit various co-morbidities, including dyslipidemia. The prevalence of dyslipidemias in children with CKD and ESRD is high (39-65 %), but is significantly dependent on the cause and vintage of CKD (e.g., usually more common and severe with glomerular disease and proteinuria) and the stage of the disease [4,5]. The Chronic Kidney Disease in Children (CKiD) study included an assessment of the relationship between renal function and serum lipid levels. The most common type of dyslipidemia was hypertriglyceridemia. They found an inverse relationship between renal function (measured glomerular filtration rate, or GFR) and serum TG and total cholesterol (TC) levels; that is, as GFR declines, TG and TC levels generally increase. Conversely, there is a ...

show abstract

“…statins, clopidogrel, acetylsalicylic acid, beta-blockers, and angiotensin-converting enzyme [ACE] inhibitors) despite the poor level of direct evidence of benefit for some of these drugs [11]. Indeed, multicentre randomized trials have failed to show a benefit of statin therapy in dialysis patients [12,13], thus suggesting that cardiovascular disease in patients undergoing hemodialysis is different than in other patients [14,15].…”

mentioning

confidence: 99%